Vertex, Regeneron speculated to be merger targets, TheStreet says Among the predictions for the biotech sector in 2014 made by David Sobek of TheStreet.com was a call for "at least two" mergers between large-cap companies. Sobek predict Sanofi (SNY) will buy Regeneron (REGN) and that Bristol-Myers Squibb (BMY) will acquire Vertex Pharmaceuticals (VRTX). Reference Link
CHMP recommends granting marketing authorization for Xigduo The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for Xigduo, 5 mg/850 mg and 5 mg/1,000 mg film-coated tablets intended for the treatment of type 2 diabetes mellitus in adults. The applicant for this medicinal product is Bristol-Myers Squibb (BMY) and AstraZeneca (AZN).